Company Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies.
The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.
In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.
Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu.
It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH.
PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Frank Bedu-Addo |
Contact Details
Address: 303A College Road East Princeton, New Jersey 08540 United States | |
| Phone | 800 208 3343 |
| Website | pdsbiotech.com |
Stock Details
| Ticker Symbol | PDSB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001472091 |
| CUSIP Number | 70465T107 |
| ISIN Number | US70465T1079 |
| Employer ID | 26-4231384 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frank K. Bedu-Addo Ph.D. | President, Chief Executive Officer and Director |
| Dr. Gregory L. Conn Ph.D. | Chief Scientific Officer |
| Lars Robert Boesgaard M.B.A. | Principal Financial and Accounting Officer and Chief Financial Officer |
| Stephan Toutain M.B.A., M.S. | Chief Operating Officer |
| Spencer Brown J.D. | Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Kirk V. Shepard M.D. | Chief Medical Officer |
| Janetta Trochimiuk | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 424B5 | Filing |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 8-K | Current Report |